Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0K5HI
|
||||
| Former ID |
DCL000241
|
||||
| Drug Name |
Talnetant
|
||||
| Synonyms |
Talnetant [INN]; SB 223412; SB-223412; N-((S)-alpha-Ethylbenzyl)-3-hydroxy-2-phenylcinchoninamide;N-(alpha-Ethylbenzyl)-3-hydroxy-2-phenylquinoline-4-carboxamide; 3-hydroxy-2-phenyl-N-(1-phenylpropyl)quinoline-4-carboxamide
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Irritable bowel syndrome [ICD9: 564.1, 787.91; ICD10:A09, K58, K59.1] | Discontinued in Phase 2 | [1], [2] | ||
| Schizophrenia; Schizoaffective disorders [ICD9: 295, 295.70; ICD10:F20, F25] | Discontinued in Phase 2 | [1], [2] | |||
| Company |
GlaxoSmithKline
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C25H22N2O2
|
||||
| InChI |
InChI=1S/C25H22N2O2/c1-2-20(17-11-5-3-6-12-17)27-25(29)22-19-15-9-10-16-21(19)26-23(24(22)28)18-13-7-4-8-14-18/h3-16,20,28H,2H2,1H3,(H,27,29)/t20-/m0/s1
|
||||
| InChIKey |
BIAVGWDGIJKWRM-FQEVSTJZSA-N
|
||||
| CAS Number |
CAS 174636-32-9
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Nigral tachykinin NK(3) receptor | Target Info | Antagonist | [3], [4], [5] | |
| KEGG Pathway | Calcium signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| Reactome | G alpha (q) signalling events | ||||
| WikiPathways | Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| Peptide GPCRs | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313. | ||||
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2132). | ||||
| REF 3 | Augmentation of antipsychotic-induced neurochemical changes by the NK3 receptor antagonist talnetant (SB-223412). Neuropharmacology. 2009 Feb;56(2):342-9. Epub 2008 Sep 18. | ||||
| REF 4 | The tachykinin NK3 receptor agonist senktide induces locomotor activity in male Mongolian gerbils. Eur J Pharmacol. 2008 Dec 14;600(1-3):87-92. Epub 2008 Oct 10. | ||||
| REF 5 | Pharmacological characterization of senktide-induced tail whips. Neuropharmacology. 2009 Jun 21. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.